Neogene Therapeutics to develop personalized cell therapies

By The Science Advisory Board staff writers

September 14, 2020 -- Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series A financing.

Neogene was founded in 2018 to advance the development of neoantigen T-cell therapies. Now, its proprietary platform allows for the isolation of neoantigen specific T-cell receptor (TCR) genes from tumor biopsies.

Tumor-infiltrating lymphocytes obtained from tumor biopsies express TCR specific for the mutated proteins found in cancer cells (neoantigens). Using DNA sequencing, DNA synthesis, and genetic screening tools, the company can identify neoantigen specific T-cell receptor genes that are subsequently engineered into personalized T cells to be used in T-cell therapies.

Initial seed funding in 2019 enabled Neogene to achieve proof of concept for its neoantigen technology platform. With the new financing, the company intends to further develop its technology with growing offices in Amsterdam and the U.S. with the goal to initiate phase I clinical studies in 2022.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here